drugset / Trial / NCT01648790

A Study of Prasugrel in Healthy Participants

NCT01648790

Phase 1 Completed 20 enrolled Eli Lilly and Company Daiichi Sankyo · collab
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to evaluate the amount of drug available in the body when given to healthy participants as two different formulations with or without a meal. In addition, this study will evaluate how much of the drug gets into the blood stream and how long the body takes to get rid of it. Information about any side effects that may occur will also be collected. Each participant will receive a total of five different treatments. Each treatment is given by mouth, once a day. The treatment period lasts for five consecutive days.

Timeline

Start
2012-07
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Prasugrel Small molecule 2 mg Oral
Subject Prasugrel Small molecule 5 mg Oral

Indications

No indication recorded.